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ScienceDirectOsteoarthritis (OA) is a degenerative joint disease and the most
common form of arthritis. Characterised by articular cartilage
loss, subchondral bone thickening and osteophyte formation,
the OA joint afflicts much pain and disability. Whilst OA has
been associated with many contributing factors, its
underpinning molecular mechanisms are, nevertheless, not
fully understood. Clinical management of OA is largely palliative
and there is an ever growing need for an effective disease
modifying treatment. This review discusses some of the recent
progress in OA therapies in the different joint tissues affected
by OA pathology.
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Introduction
With our ever ageing population comes a significant
increase in the incidence of musculoskeletal disease
and an acute need for effective therapeutic interventions.
Osteoarthritis (OA) is a degenerative joint disease and the
most common form of arthritis with 33% of people aged
45 years and over seeking treatment for OA in the UK. It
is therefore a massive world-wide healthcare and financial
burden. Characterised by articular cartilage (AC) loss,
subchondral bone thickening and osteophyte formation,
the OA joint afflicts much pain and disability [1].
Whilst OA has been associated with many contributing
factors including ageing, obesity, trauma, genetics,
amongst others, its underpinning molecular mechanisms
are, nevertheless, not fully understood; indeed it is even
still a matter of debate as to which is the precipitating
pathology. Now regarded as a disease of the whole joint,Current Opinion in Pharmacology 2016, 28:8–13 clinical management of OA is largely palliative with the
use of opioids, non-steroidal anti-inflammatory drugs
(NSAIDs) and steroid injections. In some individuals,
only prostheses can offer long-term aid.
Clinical trials to date have included glucosamine sulfate,
chondroitin sulfate, sodium hyaluronan, doxycycline, and
matrix metalloproteinases (MMP) inhibitors; all of which
have varying levels of efficacy and none of which have
successfully and reproducibly prevented OA disease de-
velopment or progression. As such, there is an ever
growing need for an effective disease modifying treat-
ment. Whilst our understanding of the aetiopathology of
OA is dramatically advancing, few advances have been
made in the pharmacological intervention of disease
progression. This review discusses some of the most
recent progress in OA therapies in the different joint
tissues affected by OA pathology that were not already
discussed by the recent review published in this journal in
2015 [2].
Targeting AC maintenance
AC degradation is one of the main hallmarks of OA
development and to date, research has largely sought
to identify those factors that target the AC to produce
its disease-defining deterioration. However, the lack of
blood vessels and the high ratio of extracellular matrix to
cell area make this tissue difficult to target for repair;
indeed pharmaceutical interventions are usually reliant
on blood circulation of compounds through the body and
to the cells through the matrix. An elegant and compre-
hensive review in this journal has recently summarised
the most recent advances in finding new targets for
reducing AC degradation, including cartilage degrada-
tion, autophagy, circadian clock, mechanical, inflamma-
tory, oxidative stress, innate immunity, chondrocyte
hypertrophy, pain [2]. In addition to those mentioned
by Goldring and Berenbaum [2], further targets have
recently been examined and are discussed herein.
Oxidative stress is emerging as a main contributor to OA
severity. Recently, pathways centred around Heme Oxy-
genase 1 (HO-1), a major anti-oxidant, have been shown
to play a major role in the oxidative stress response in
chondrocytes. Indeed, Bach-1 (BTB and CNC homology)
is a negative regulator of HO-1, and its deletion in mouse
chondrocytes in vivo was shown to protect from OA
development, via the promotion of HO-1 and autophagy
[3]. In addition, Nrf2 (nuclear factor (erythroid-derived
2)-like 2) is a promotor of HO-1 expression, and itswww.sciencedirect.com
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[4]. This effect was reduced with a histone deacetylase
inhibitor (trichostatin A) following Nrf2 activation and
HO-1 expression. Sulfuraphane was used a potent acti-
vator of Nrf2, inducing HO-1 expression, and decreased
cartilage degradation in a murine post-traumatic model of
OA [5]. These studies support HO-1 as a potent new
target for cartilage degradation in OA.
TGFa (Transforming Growth Factor-a) is a member of
the epidermal growth factor (EGF) family and has been
shown to be increased by 4 fold in the AC of OA rats [6]. It
was subsequently found that TGFa can reduce chondro-
cyte anabolism while increasing catabolic processes and
thus was proposed to be a potential target for therapy for
AC degradation in OA development [7]. Recently,
Appleton et al. (2015) used pharmacological tools, namely
AG1478, to inhibit TGFa in vivo in a rat OA model [8].
AG1478 was able to reduce cartilage degradation and OA
severity, as well as increasing the levels of CPII (C-
propeptide of collagen type II) in the serum while de-
creasing C2C (collagen type II breakdown product)
levels, markers of cartilage anabolism and catabolism
respectively. This study is one of the first to show phar-
macologic efficacy in blocking post-traumatic OA devel-
opment in vivo.
AC matrix degradation products have been shown to
promote further joint degeneration. Indeed, fragments
of collagen type II, aggrecan and fibronectin can induce
further degradation through upregulation of MMP activ-
ity [9–11]. However, a complex interaction between
specific fragments and concentration and mechanical
stress may result in anabolic responses as well [12].
The signalling involved in these responses seems to be
similar between cell types: indeed, Lees et al. [13] re-
cently described the effect of an aggrecan 32-mer frag-
ment derived from ADAMTS (A Disintegrin And
Metalloproteinase with Thrombospondin Motifs)and
MMP cleavage of aggrecan on chondrocytes, synovial
fibroblasts and macrophages [13]. Treatment with this
aggrecan 32-mer fragment resulted in pro-catabolic, anti-
anabolic and pro-inflammatory activities, which were all
abrogated in the absence of MyD88 (myeloid differenti-
ation primary response gene 88), and was achieved via
Toll-Like Receptor 2-dependent activation of the signal-
ling pathway NFkB (nuclear factor kappa-light-chain-
enhancer of activated B cells). This same pathway was
also shown to be responsible for Fibronectin fragment
catabolic responses from chondrocytes, suggesting poten-
tial targets for slowing the progressive degeneration of the
AC in OA [14].
Although very informative, these studies have been per-
formed in animal models, and thus further trials into
human tissues and patients will be required to truly
understand the potential of these targets for therapy.www.sciencedirect.com Targeting the subchondral bone
Subchondral bone pathologies in OA joints, although
often considered secondary, are one of the earliest de-
tectable changes and are now considered to be a potential
trigger for subsequent OA progression [15,16]. These
pathologies include sclerosis leading to joint space nar-
rowing, with associated hypomineralisation and inferior
bone quality due to abnormal local bone remodelling. It is
therefore unsurprising that pharmacological interventions
for the subchondral bone in OA have focussed on target-
ing regulation of osteoclast/osteoblast activity and as such,
the bone remodelling process.
Inhibition of osteoclast activity
Bisphosphonates are potent inhibitors of osteoclast activ-
ity, and are widely used in clinical practice to prevent the
bone loss associated with conditions such as Paget’s
disease, metastatic bone disease and osteoporosis [17].
The use of bisphosphonates as means of OA therapies has
been well investigated over the past decade with varying
efficacy, and as such, more recent pharmacological studies
have focussed upon the timing at which treatment with
anti-resorptive agents should be used for disease modifi-
cation [18]. Pamidronate disodium (PAM) is a bispho-
sphate which completely prevents OA pathology in
rabbits undergoing early anterior cruciate ligament
transection (ACLT)-induced OA when administered
short-term post ACLT. Similarly, long-term PAM admin-
istration reverses OA pathology in this model. This is
therefore suggestive that PAM can significantly inhibit
and even reverse early OA subchondral bone pathology,
thought to be through OPG:RANKL (Osteoprote-
gerin — Receptor Activator of NFkB Ligand) mediated
regulation of osteoclastogenesis [19]. Similarly, the pre-
emptive use of another bisphosphonate, Alendronate, in a
rat model for severe OA prevents OA bone pathologies
including reduced subchondral bone loss and reduced
osteophyte formation when compared to non-alendronate
treated rats. Alendronate treatment also reduced AC
degeneration, suggesting that osteoclastic activity drives
AC degeneration [20]. Similar chondroprotective effects
of the bisphosphonates clodronate and zoledronic acid
have been reported on bovine chondrocyte cultures and
ACLT in rabbits, respectively [21,22].
Whilst animal studies are informative, clinical trials are
required to investigate the true therapeutic value of
bisphosphonates in human OA. In the past two years
there have been four clinical trials detailing the effects of
bisphosphonates on human OA, with varying results.
Nishii et al. found that 2 years alendronate treatment
in patients with symptomatic hip OA revealed clinical
efficacy for decreasing pain. Despite this, no differences
were observed in OA disease pathology, as determined by
radiographic measurements of Kellgren-Lawrence score,
joint space narrowing and centre-edge angle [23]. Similar
advantages for bisphosphonate use in improving painCurrent Opinion in Pharmacology 2016, 28:8–13
10 Musculoskeletalsymptoms were reported in patients undergoing 4 weeks
clodronate treatment for symptomatic knee OA [24]. A
more recent randomised controlled trial investigating
patients for 7 years following total knee replacement
did however find that a year post-operative alendronate
treatment significantly changed the mean bone mineral
density of the femoral metaphysis up to four years fol-
lowing surgery, suggestive that alendronate treatment
may be of benefit to patients following total knee replace-
ment surgery [25]. Similarly, another study examining
the progression of OA found a trend to less joint space
narrowing over time in bisphosphonate users in compari-
son to non-users [18].
Together this suggests that bisphosphonates may have
beneficial symptomatic and structural benefits for
patients with OA, however many larger clinical studies
are required to evaluate their true potential.
Modifications of osteoblasts activities
As well as targeting osteoclasts in bone remodelling,
studies have sought to identify whether the osteoblast
is key to OA therapies. In the natural occurring OA guinea
pig model, subcutaneous injections of Parathyroid Hor-
mone (PTH) at a dosage of 15 mg/kg/day for five days/
week for 3 and 6 months has advantageous effects on OA
progression through decreasing the deterioration of the
subchondral bone trabeculae and ultimately preventing
AC degradation [26]. Similarly, in a rabbit model in which
cylindrical osteochondral defects were created in the
femoral trochlea, PTH treatment stimulated both sub-
chondral bone and AC repair [27]. Consistent with this,
2 year treatment with calcitonin which reverses the
effects of PTH had no structural effects on joint space
narrowing and although an improvement in pain and
functionality, this was not deemed significant in patients
with symptomatic knee OA [28]. PTH stimulates the
activation of Vitamin D. Vitamin D deficiency itself has
been associated with the development and worsening of
knee OA [29]. Indeed supplementation of vitamin D in
patients with vitamin D deficiency significantly improves
knee pain and function in patients with symptomatic
knee OA in comparison to placebo, although no structural
changes were observed, suggesting that vitamin D may be
having cellular effects that improve pain but do not yet
influence bone microarchitecture [30]. Indeed it is possi-
ble that vitamin D in this study is influencing angiogene-
sis, as has been previously reported, to influence pain [31].
Similar results were observed in a 2 year vitamin D
supplementation study in which supplementation had
no effect on OA progression in patients with symptomatic
OA but did however have greater effects overall on
patients with lower basal levels of vitamin D [32]. This
highlights the need for a larger study with a longer follow-
up period, and in particular, the need to distinguish
between the different subtypes of OA when in pursuit
of a disease modifying treatment.Current Opinion in Pharmacology 2016, 28:8–13 Bone cell signalling in OA
Canonical Wnt signalling plays critical roles in a number
of biological processes during development and tissue
homeostasis, with pathway activation leading to in-
creased bone formation [33]. Numerous inhibitors of this
pathway have been identified including Dkk1 (Dickkopf
WNT signalling pathway inhibitor 1), sclerostin, and
sFRP3 (secreted Frizzled-Related Protein 3), all of
which have altered expression patterns during OA de-
velopment, with sFRP3 being identified as having ge-
netic polymorphisms associated with OA development
[34–36]. In humans, sclerostin mutations present as Van
Buchem’s disease and sclerosteosis, both of which pres-
ent as a high bone mass phenotype, as does the sclerostin
knockout mouse [37–39]. It is therefore unsurprising that
numerous sclerostin neutralising antibodies have been
developed and investigated for therapeutic intervention
against osteoporosis [40–42]. However, whether such
antibodies could be pursued as a target for OA treatment
is somewhat a matter of contention. Studies by Roudier
et al. have shown that sclerostin neutralising antibodies
have no benefit on OA development in aged mice or in
mice having undergone mechanical and surgical OA
models [43]. However, it is of some concern that other
studies have shown that increased Wnt signalling activa-
tion induces an OA phenotype [44]; indeed mice defi-
cient in sclerostin have an attenuated OA pathology in
response to DMM (Destabilisation of the Medial Menis-
cus) [45]. Similarly, overexpression of Dkk1 by intra-
articular injection of Dkk1 adenoviruses significantly
inhibits DMM-induced OA pathology [46]. Knowing
the complexities of the Wnt signalling pathway, it is
therefore unsurprising that such controversies exist
and future work should perhaps focus on deciphering
the precise role of Wnt activation on subchondral bone
phenotype so as to avoid any off target effects through
which the inhibitors of Wnt signalling may be working
through.
The Wnt pathway works co-operatively with Bone Mor-
phogenetic Proteins (BMP) which are members of the
Transforming Growth Factor-b (TGF-b) superfamily
unique in regulating the differentiation and function of
both osteoblasts and osteoclasts to mediate bone remo-
delling and maintain bone homeostasis. With significant
roles in AC homeostasis as well, it is therefore unsurpris-
ing that there is increasing evidence implicating both
BMP and TGF-b signalling in the pathogenesis of OA.
Halofuginone is a derivative of febrifugine, an ancient
Chinese herbal medicine that inhibits TGF-b signalling.
In mice undergoing ACLT, halofuginone accelerated
subchondral bone deterioration through attenuating
uncoupled subchondral bone remodelling and excessive
subchondral bone angiogenesis. This was associated with
the inhibition of T-helper-17-induced osteoclastogenesis
and excessive TGF-b activity [47]. Contradictory to
this, inhibition of TGF-b signalling through injection of awww.sciencedirect.com
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mice rescued the OA phenotype [48]. It is likely that any
changes in TGF-b signalling in the subchondral bone will
lead to articular cartilage degeneration as shown in TGF-
b overexpressing mice [49].
Angiogenesis
Increased angiogenic activity leading to increased vascu-
lar invasion of the subchondral bone has been reported in
the early stages of OA in both animal models and in
human patients [50–53]. As such, osteochondral angio-
genesis is thought to contribute to the aetiopathogenesis
of OA and pharmacological agents which act to inhibit
such processes are being targeted in pursuit of an OA
therapy. Halofuginone, as discussed previously, acts via
TGF-b to inhibit angiogenesis through the direct inhibi-
tion of MMP2-dependent vessel formation. It is known
that TGF-b inhibition can reduce angiogenesis in sub-
chondral bone in ACLT OA mice [48] and these results
have also been observed upon administration of halofu-
ginone [47]. Similarly, local intra-articular administra-
tion of Bevacizumab, an anti-vascular endothelial growth
factor (VEGF) antibody, has beneficial results on OA
development in a rabbit model of ACLT [54], whilst
the injection of VEGF in to the temporomandibular joint
of mice over a period of 4 weeks induces an OA pheno-
type with both subchondral bone and AC pathologies
[55]. This therefore implicates targeting of angiogenesis
in subchondral bone as an exciting new approach for
future endeavours to find a disease modifying treatment
for OA.
Together, this body of work highlights the potent role
that the subchondral bone plays in OA aetiology. It also
highlights the therapeutic potential that the subchondral
bone offers when approaching targets for investigation
and is in concordance with the notion that OA should be
categorised into subtypes of disease.
Targeting the synovial membrane
Synovial fibrosis is a major hallmark of OA pathogenesis,
contributing to joint pain and stiffness. Various compo-
nent of the synovial fibrotic cascade have been examined,
including TGF-b, Connective Tissue Growth Factor and
TIMP1 (Tissue Inhibitor of MMP-1), however these
were also suggested as not being attractive targets for
OA therapy since these factors are known to promote
anabolic responses from chondrocytes and inhibit carti-
lage matrix degradation; hence their inhibition might in
fact accelerate AC degradation [56]. A better target was
proposed such as PLOD2 (Procollagen-Lysine, 2-Oxo-
glutarate 5-Dioxygenase 2). Indeed, PLOD2 is a collagen
cross-linking enzyme, which is increased during fibrosis
and OA, and makes the collagen less susceptible to
degradation [57,58]. Studies are yet to establish however,
whether the pharmacological targeting of PLOD2 is
beneficial to OA progression.www.sciencedirect.com MicroRNAs are novel molecular regulators of gene expres-
sion and contribute to disease pathogenesis. These small
coding RNAs represent a new class of therapeutic targets
for many diseases. Some studies have used miRNA as a
therapeutic agent; indeed, large quantities of miR-34a was
successfully bioengineered and injected intravenously in
combination with another drug against tumour growth in
mice, confirming the possibility of using miRNAs as ther-
apeutic agents [59]. Only one study to date has used intra-
articular injection of miRNA [60]. Their aim was to
investigate whether double-stranded miR-15a could be
taken up by cells. MiR-15a was detected in the synovium,
but not in the AC, suggesting miRNA may be used as
therapeutic agents to treat non-cartilage tissues in OA
pathogenesis such as synovial fibrosis, and might even
be beneficial in avoiding negative effects on the AC. This
method was subsequently used in other studies in rheu-
matoid arthritis studies in mice [61–63].
Conclusions
OA is a complex multifactorial disease, which affects
different tissues in the joint. To date, clinical manage-
ment of OA is largely palliative with the use of opioids,
Non-steroidal anti-inflammatory drugs and steroid injec-
tions with only prostheses can offer long-term aid in some
individuals. Whilst numerous clinical trials have investi-
gated various pharmacological targets, there have been
varying efficacies reported and with our ever ageing
population, the need for an effective disease modifying
treatment is paramount. Possible avenues reside in block-
ing further deterioration of the AC but also on the
prevention of subchondral bone thickening or treating
synovial changes, with numerous targets discussed within
this review. Whilst animal studies are informative, larger
and more diverse clinical trials are required to investigate
the true efficacy of such targets in preventing OA onset
and progression.
Conflict of interest statement
Nothing declare.
Acknowledgements
The authors wish to acknowledge Arthritis Research UK for funding (20413
and 20859).
References and recommended reading
Papers of particular interest, published within the period of review,
have been highlighted as:
 of special interest
 of outstanding interest
1. Goldring MB, Goldring SR: Articular cartilage and subchondral
bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci
2010, 1192:230-237.
2.

Goldring MB, Berenbaum F: Emerging targets in osteoarthritis
therapy. Curr Opin Pharmacol 2015, 22:51-63.
Comprehensive recent review on cartilage targets for OA.
3.

Takada T, Miyaki S, Ishitobi H, Hirai Y, Nakasa T, Igarashi K,
Lotz MK, Ochi M: Bach1 deficiency reduces severity ofCurrent Opinion in Pharmacology 2016, 28:8–13
12 Musculoskeletalosteoarthritis through upregulation of heme oxygenase-1.
Arthritis Res Ther 2015, 17:285.
Description of HO-1 related pathway to decrease OA development in
mice.
4. Cai D, Yin S, Yang J, Jiang Q, Cao W: Histone deacetylase
inhibition activates Nrf2 and protects against osteoarthritis.
Arthritis Res Ther 2015, 17:269.
5. Davidson RK, Jupp O, de Ferrars R, Kay CD, Culley KL, Norton R,
Driscoll C, Vincent TL, Donell ST, Bao Y et al.: Sulforaphane
represses matrix-degrading proteases and protects cartilage
from destruction in vitro and in vivo. Arthritis Rheum 2013,
65:3130-3140.
6. Appleton CT, Pitelka V, Henry J, Beier F: Global analyses of gene
expression in early experimental osteoarthritis. Arthritis Rheum
2007, 56:1854-1868.
7.

Appleton CT, Usmani SE, Bernier SM, Aigner T, Beier F:
Transforming growth factor alpha suppression of articular
chondrocyte phenotype and Sox9 expression in a rat model of
osteoarthritis. Arthritis Rheum 2007, 56:3693-3705.
Effect of targeting TGFa showing pharmacological efficacy in blocking
post-traumatic OA in vivo.
8. Appleton CT, Usmani SE, Pest MA, Pitelka V, Mort JS, Beier F:
Reduction in disease progression by inhibition of transforming
growth factor alpha-CCL2 signaling in experimental
posttraumatic osteoarthritis. Arthritis Rheumatol 2015,
67:2691-2701.
9. Yasuda T: Cartilage destruction by matrix degradation
products. Mod Rheumatol 2006, 16:197-205.
10. Fichter M, Korner U, Schomburg J, Jennings L, Cole AA,
Mollenhauer J: Collagen degradation products modulate
matrix metalloproteinase expression in cultured articular
chondrocytes. J Orthop Res 2006, 24:63-70.
11. Stanton H, Fosang AJ: Matrix metalloproteinases are active
following guanidine hydrochloride extraction of cartilage:
generation of DIPEN neoepitope during dialysis. Matrix Biol
2002, 21:425-428.
12. Chowdhury TT, Schulz RM, Rai SS, Thuemmler CB, Wuestneck N,
Bader A, Homandberg GA: Biomechanical modulation of
collagen fragment-induced anabolic and catabolic activities in
chondrocyte/agarose constructs. Arthritis Res Ther 2010,
12:R82.
13. Lees S, Golub SB, Last K, Zeng W, Jackson DC, Sutton P,
Fosang AJ: Bioactivity in an aggrecan 32-mer fragment is
mediated via toll-like receptor 2. Arthritis Rheumatol 2015,
67:1240-1249.
14. Hwang HS, Park SJ, Cheon EJ, Lee MH, Kim HA: Fibronectin
fragment-induced expression of matrix metalloproteinases is
mediated by MyD88-dependent TLR-2 signaling pathway in
human chondrocytes. Arthritis Res Ther 2015, 17:320.
15. Mansell JP, Collins C, Bailey AJ: Bone, not cartilage, should be
the major focus in osteoarthritis. Nat Clin Pract Rheumatol 2007,
3:306-307.
16. Karsdal MA, Leeming DJ, Dam EB, Henriksen K, Alexandersen P,
Pastoureau P, Altman RD, Christiansen C: Should subchondral
bone turnover be targeted when treating osteoarthritis?
Osteoarthr Cartil 2008, 16:638-646.
17. Russell RG: Bisphosphonates: from bench to bedside. Ann N Y
Acad Sci 2006, 1068:367-401.
18.

Laslett LL, Kingsbury SR, Hensor EM, Bowes MA, Conaghan PG:
Effect of bisphosphonate use in patients with symptomatic
and radiographic knee osteoarthritis: data from the
Osteoarthritis Initiative. Ann Rheum Dis 2014, 73:824-830.
Examines the use of bisphosphonates on the symptoms and structural
progression of OA.
19. Lv Y, Xia JY, Chen JY, Zhao H, Yan HC, Yang HS, Li Q, Fan YX,
Guo KJ, Chen XY: Effects of pamidronate disodium on the loss
of osteoarthritic subchondral bone and the expression of
cartilaginous and subchondral osteoprotegerin and RANKL in
rabbits. BMC Musculoskelet Disord 2014, 15:370.Current Opinion in Pharmacology 2016, 28:8–13 20. Siebelt M, Waarsing JH, Groen HC, Muller C, Koelewijn SJ, de
Blois E, Verhaar JA, de Jong M, Weinans H: Inhibited
osteoclastic bone resorption through alendronate treatment
in rats reduces severe osteoarthritis progression. Bone 2014,
66:163-170.
21. Rosa RG, Collavino K, Lakhani A, Delve E, Weber JF, Rosenthal AK,
Waldman SD: Clodronate exerts an anabolic effect on articular
chondrocytes mediated through the purinergic receptor
pathway. Osteoarthr Cartil 2014, 22:1327-1336.
22. Lampropoulou-Adamidou K, Dontas I, Stathopoulos IP, Khaldi L,
Lelovas P, Vlamis J, Triantafillopoulos IK, Papaioannou NA:
Chondroprotective effect of high-dose zoledronic acid: an
experimental study in a rabbit model of osteoarthritis. J Orthop
Res 2014, 32:1646-1651.
23. Nishii T, Tamura S, Shiomi T, Yoshikawa H, Sugano N:
Alendronate treatment for hip osteoarthritis: prospective
randomized 2-year trial. Clin Rheumatol 2013, 32:1759-1766.
24. Rossini M, Adami S, Fracassi E, Viapiana O, Orsolini G, Povino MR,
Idolazzi L, Gatti D: Effects of intra-articular clodronate in the
treatment of knee osteoarthritis: results of a double-blind,
randomized placebo-controlled trial. Rheumatol Int 2015,
35:255-263.
25.

Jaroma AV, Soininvaara TA, Kroger H: Effect of one-year post-
operative alendronate treatment on periprosthetic bone after
total knee arthroplasty. A seven-year randomised controlled
trial of 26 patients. Bone Joint J 2015, 97-B:337-345.
Suggests that bisphosphonate treatment after total knee replacement
may be beneficial.
26. Yan JY, Tian FM, Wang WY, Cheng Y, Song HP, Zhang YZ,
Zhang L: Parathyroid hormone (1–34) prevents cartilage
degradation and preserves subchondral bone micro-
architecture in guinea pigs with spontaneous osteoarthritis.
Osteoarthr Cartil 2014, 22:1869-1877.
27.

Orth P, Cucchiarini M, Zurakowski D, Menger MD, Kohn DM,
Madry H: Parathyroid hormone [1–34] improves articular
cartilage surface architecture and integration and
subchondral bone reconstitution in osteochondral defects in
vivo. Osteoarthr Cartil 2013, 21:614-624.
Determines that PTH treatment stimulates both articular cartilage and
subchondral bone repair in an in vivo osteochondral defect model.
28. Karsdal MA, Byrjalsen I, Alexandersen P, Bihlet A, Andersen JR,
Riis BJ, Bay-Jensen AC, Christiansen C, investigators CC:
Treatment of symptomatic knee osteoarthritis with oral
salmon calcitonin: results from two phase 3 trials. Osteoarthr
Cartil 2015, 23:532-543.
29. Heidari B, Heidari P, Hajian-Tilaki K: Association between serum
vitamin D deficiency and knee osteoarthritis. Int Orthop 2011,
35:1627-1631.
30. Sanghi D, Mishra A, Sharma AC, Singh A, Natu SM, Agarwal S,
Srivastava RN: Does vitamin D improve osteoarthritis of the
knee: a randomized controlled pilot trial. Clin Orthop Relat Res
2013, 471:3556-3562.
31. Grundmann M, Haidar M, Placzko S, Niendorf R, Darashchonak N,
Hubel CA, von Versen-Hoynck F: Vitamin D improves the
angiogenic properties of endothelial progenitor cells. Am J
Physiol Cell Physiol 2012, 303:C954-C962.
32. McAlindon T, LaValley M, Schneider E, Nuite M, Lee JY, Price LL,
Lo G, Dawson-Hughes B: Effect of vitamin D supplementation
on progression of knee pain and cartilage volume loss in
patients with symptomatic osteoarthritis: a randomized
controlled trial. JAMA 2013, 309:155-162.
33. Staines KA, Macrae VE, Farquharson C: Cartilage development
and degeneration: a Wnt Wnt situation. Cell Biochem Funct
2012.
34. Chan BY, Fuller ES, Russell AK, Smith SM, Smith MM,
Jackson MT, Cake MA, Read RA, Bateman JF, Sambrook PN
et al.: Increased chondrocyte sclerostin may protect against
cartilage degradation in osteoarthritis. Osteoarthr Cartil 2011,
19:874-885.
35. Loughlin J, Dowling B, Chapman K, Marcelline L, Mustafa Z,
Southam L, Ferreira A, Ciesielski C, Carson DA, Corr M:www.sciencedirect.com
New developments in osteoarthritis Poulet and Staines 13Functional variants within the secreted frizzled-related protein
3 gene are associated with hip osteoarthritis in females. Proc
Natl Acad Sci U S A 2004, 101:9757-9762.
36. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D,
Korb A, Smolen J, Hoffmann M, Scheinecker C et al.: Dickkopf-1
is a master regulator of joint remodeling. Nat Med 2007,
13:156-163.
37. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M,
Lacza C, Wuyts W, Van Den Ende J, Willems P et al.: Increased
bone density in sclerosteosis is due to the deficiency of a
novel secreted protein (SOST). Hum Mol Genet 2001,
10:537-543.
38. van Bezooijen RL, Bronckers AL, Gortzak RA, Hogendoorn PC,
van der Wee-Pals L, Balemans W, Oostenbroek HJ, Van Hul W,
Hamersma H, Dikkers FG et al.: Sclerostin in mineralized
matrices and van Buchem disease. J Dent Res 2009,
88:569-574.
39. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D’Agostin D,
Kurahara C, Gao Y, Cao J, Gong J et al.: Targeted deletion of the
sclerostin gene in mice results in increased bone formation
and bone strength. J Bone Miner Res 2008, 23:860-869.
40. Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ,
Dwyer D, Han CY, Vlasseros F et al.: Inhibition of sclerostin by
monoclonal antibody enhances bone healing and improves
bone density and strength of nonfractured bones. J Bone Miner
Res 2011, 26:1012-1021.
41. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J,
Gao Y, Shalhoub V, Tipton B, Haldankar R et al.: Sclerostin
antibody treatment increases bone formation, bone mass, and
bone strength in a rat model of postmenopausal osteoporosis.
J Bone Miner Res 2009, 24:578-588.
42. Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M,
Dwyer D, Stouch B, Thway TM, Stolina M et al.: Inhibition of
sclerostin by monoclonal antibody increases bone formation,
bone mass, and bone strength in aged male rats. J Bone Miner
Res 2010, 25:2647-2656.
43. Roudier M, Li X, Niu QT, Pacheco E, Pretorius JK, Graham K,
Yoon BR, Gong J, Warmington K, Ke HZ et al.: Sclerostin is
expressed in articular cartilage but loss or inhibition does not
affect cartilage remodeling during aging or following
mechanical injury. Arthritis Rheum 2013, 65:721-731.
44. Zhu M, Tang DZ, Wu QQ, Hao SY, Chen M, Xie C, Rosier RN,
O’Keefe RJ, Zuscik M, Chen D: Activation of beta-catenin
signaling in articular chondrocytes leads to osteoarthritis-like
phenotype in adult beta-catenin conditional activation mice. J
Bone Miner Res 2009, 24:12-21.
45. Bouaziz W, Funck-Brentano T, Lin H, Marty C, Ea HK, Hay E,
Cohen-Solal M: Loss of sclerostin promotes osteoarthritis in
mice via beta-catenin-dependent and -independent Wnt
pathways. Arthritis Res Ther 2015, 17:24.
46. Oh H, Chun CH, Chun JS: Dkk-1 expression in chondrocytes
inhibits experimental osteoarthritic cartilage destruction in
mice. Arthritis Rheum 2012, 64:2568-2578.
47.

Cui Z, Crane J, Xie H, Jin X, Zhen G, Li C, Xie L, Wang L, Bian Q,
Qiu T et al.: Halofuginone attenuates osteoarthritis by inhibition
of TGF-beta activity and H-type vessel formation in
subchondral bone. Ann Rheum Dis 2015.
Suggests that inhibition of TGF-b signalling, through administration of
halofuginone, attenuates subchondral bone, and articular cartilage
pathologies in an ACLT-rat model, as well as aberrant angiogenesis.
48. Zhen G, Wen C, Jia X, Li Y, Crane JL, Mears SC, Askin FB,
Frassica FJ, Chang W, Yao J et al.: Inhibition of TGF-beta
signaling in mesenchymal stem cells of subchondral bone
attenuates osteoarthritis. Nat Med 2013, 19:704-712.
49. Jiao K, Zhang M, Niu L, Yu S, Zhen G, Xian L, Yu B, Yang K, Liu P,
Cao X et al.: Overexpressed TGF-beta in subchondral bonewww.sciencedirect.com leads to mandibular condyle degradation. J Dent Res 2014,
93:140-147.
50. Ashraf S, Mapp PI, Walsh DA: Contributions of angiogenesis to
inflammation, joint damage, and pain in a rat model of
osteoarthritis. Arthritis Rheum 2011, 63:2700-2710.
51. Saito M, Sasho T, Yamaguchi S, Ikegawa N, Akagi R,
Muramatsu Y, Mukoyama S, Ochiai N, Nakamura J, Nakagawa K
et al.: Angiogenic activity of subchondral bone during the
progression of osteoarthritis in a rabbit anterior cruciate
ligament transection model. Osteoarthr Cartil 2012,
20:1574-1582.
52. Suri S, Gill SE, Massena de Camin S, Wilson D, McWilliams DF,
Walsh DA: Neurovascular invasion at the osteochondral
junction and in osteophytes in osteoarthritis. Ann Rheum Dis
2007, 66:1423-1428.
53. Walsh DA, McWilliams DF, Turley MJ, Dixon MR, Franses RE,
Mapp PI, Wilson D: Angiogenesis and nerve growth factor at
the osteochondral junction in rheumatoid arthritis and
osteoarthritis. Rheumatology (Oxford) 2010, 49:1852-1861.
54.

Nagai T, Sato M, Kobayashi M, Yokoyama M, Tani Y, Mochida J:
Bevacizumab, an anti-vascular endothelial growth factor
antibody, inhibits osteoarthritis. Arthritis Res Ther 2014, 16:427.
Identifies Bevacizumab as a potential therapy for OA through inhibition of
VEGF and angiogenesis.
55. Shen P, Jiao Z, Zheng JS, Xu WF, Zhang SY, Qin A, Yang C:
Injecting vascular endothelial growth factor into the
temporomandibular joint induces osteoarthritis in mice. Sci
Rep 2015, 5:16244.
56.

Remst DF, Blaney Davidson EN, van der Kraan PM: Unravelling
osteoarthritis-related synovial fibrosis: a step closer to solving
joint stiffness. Rheumatology (Oxford) 2015, 54:1954-1963.
Review on targeting the synovial membrane in OA development.
57. Remst DF, Blaney Davidson EN, Vitters EL, Blom AB, Stoop R,
Snabel JM, Bank RA, van den Berg WB, van der Kraan PM:
Osteoarthritis-related fibrosis is associated with both
elevated pyridinoline cross-link formation and lysyl
hydroxylase 2b expression. Osteoarthr Cartil 2013, 21:157-164.
58. van der Slot AJ, van Dura EA, de Wit EC, De Groot J, Huizinga TW,
Bank RA, Zuurmond AM: Elevated formation of pyridinoline
cross-links by profibrotic cytokines is associated with
enhanced lysyl hydroxylase 2b levels. Biochim Biophys Acta
2005, 1741:95-102.
59. Zhao Y, Tu MJ, Yu YF, Wang WP, Chen QX, Qiu JX, Yu AX, Yu AM:
Combination therapy with bioengineered miR-34a prodrug
and doxorubicin synergistically suppresses osteosarcoma
growth. Biochem Pharmacol 2015, 98:602-613.
60.

Nagata Y, Nakasa T, Mochizuki Y, Ishikawa M, Miyaki S,
Shibuya H, Yamasaki K, Adachi N, Asahara H, Ochi M: Induction
of apoptosis in the synovium of mice with autoantibody-
mediated arthritis by the intraarticular injection of double-
stranded MicroRNA-15a. Arthritis Rheum 2009, 60:2677-2683.
One of the first studies using intra-articular injection of miRNA as a
therapeutic agent targeting the synovium (and not the cartilage).
61. Nakasa T, Shibuya H, Nagata Y, Niimoto T, Ochi M: The inhibitory
effect of microRNA-146a expression on bone destruction in
collagen-induced arthritis. Arthritis Rheum 2011, 63:1582-1590.
62. Peng JS, Chen SY, Wu CL, Chong HE, Ding YC, Shiau AL,
Wang CR: Amelioration of experimental autoimmune arthritis
through targeting synovial fibroblasts by the intra-articular
delivery of microRNA-140-3p and -5p. Arthritis Rheumatol 2015.
63. Shibuya H, Nakasa T, Adachi N, Nagata Y, Ishikawa M, Deie M,
Suzuki O, Ochi M: Overexpression of microRNA-223 in
rheumatoid arthritis synovium controls osteoclast
differentiation. Mod Rheumatol 2013, 23:674-685.Current Opinion in Pharmacology 2016, 28:8–13
